Diagnostic Robotics, an Israel-based company that developed an AI platform that helps predict which patients will benefit from proactive interventions and improve the point of care, announced that it raised $45 million in Series B funding.
The round was led by StageOne Ventures, with participation from institutional Israeli investors Midgal Insurance, Clal Insurance, and Bank Hapoalim, as well as Mayo Clinic and the company’s existing investors.
Brad Bloom, co-founder of Berkshire Partners, and Gigi Levy-Weiss, co-founder of NFX, also participated in the round. Diagnostic Robotics has raised around $70 million to date.
The new funding will be used to accelerate product development and go-to-market growth, including investment in sales and marketing and other key hires across the organization.
Company: Diagnostic Robotics Ltd.
Round: Series B
Funding Month: Aug 2022
Lead Investors: StageOne Ventures
Additional Investors: Midgal Insurance, Clal Insurance, Bank Hapoalim, Mayo Clinic, Brad Bloom, and Gigi Levy-Weiss
Company Website: https://www.diagnosticrobotics.com/
Software Category: AI diagnostic system
About the Company: Founded in 2017, Diagnostic Robotics developed an AI platform that helps predict which patients will benefit from proactive interventions and improve the point of care. Diagnostic Robotics has helped clients carry out care management programs and leverage AI to home in on predicting patient risk in a precise and impactful way to improve patient outcomes and care paths and reduce the cost of care. Diagnostic Robotics' suite of products is currently in use at healthcare institutions, HMOs, and providers in Israel and the United States. Diagnostic Robotics is headquartered in Tel Aviv and has markets in India, Israel, and the United States.